Abstract:Background: Evidence-based treatments for depression exist but not all patients benefit from them. Efforts to develop predictive models that can assist clinicians in allocating treatments are ongoing, but there are major issues with acquiring the volume and breadth of data needed to train these models. We examined the feasibility, tolerability, patient characteristics, and data quality of a novel protocol for internet-based treatment research in psychiatry that may help advance this field. Methods: A fully internet-based protocol was used to gather repeated observational data from patient cohorts receiving internet-based cognitive behavioural therapy (iCBT) (N = 600) or antidepressant medication treatment (N = 110). At baseline, participants provided > 600 data points of self-report data, spanning socio-demographics, lifestyle, physical health, clinical and other psychological variables and completed 4 cognitive tests. They were followed weekly and completed another detailed clinical and cognitive assessment at week 4. In this paper, we describe our study design, the demographic and clinical characteristics of participants, their treatment adherence, study retention and compliance, the quality of the data gathered, and qualitative feedback from patients on study design and implementation. Results: Participant retention was 92% at week 3 and 84% for the final assessment. The relatively short study duration of 4 weeks was sufficient to reveal early treatment effects; there were significant reductions in 11 transdiagnostic psychiatric symptoms assessed, with the largest improvement seen for depression. Most participants (66%) reported being distracted at some point during the study, 11% failed 1 or more attention checks and 3% consumed an intoxicating substance. Data quality was nonetheless high, with near perfect 4-week test retest reliability for self-reported height (ICC = 0.97). Conclusions: An internet-based methodology can be used efficiently to gather large amounts of detailed patient data during iCBT and antidepressant treatment. Recruitment was rapid, retention was relatively high and data quality was good. This paper provides a template methodology for future internet-based treatment studies, showing that such an approach facilitates data collection at a scale required for machine learning and other data-intensive methods that hope to deliver algorithmic tools that can aid clinical decision-making in psychiatry.

Precision Psychiatry Implementation in Child and Adolescent Psychiatric Clinical Practice: Opportunities and Challenges

Precision psychiatry: predicting predictability

USING ELECTRONIC HEALTH RECORDS TO FACILITATE PRECISION PSYCHIATRY

How real-world data can facilitate the development of precision medicine treatment in psychiatry

Restoring the missing person to personalized medicine and precision psychiatry

The new paradigm of psychiatry precision medicine and its emerging clinical framework

Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches

Working Towards the Development and Implementation of Precision Mental Healthcare: An Example

Ambulatory assessment for precision psychiatry: Foundations, current developments and future avenues

The Precision in Psychiatry (PIP) study: Testing an internet-based methodology for accelerating research in treatment prediction and personalisation

Precision psychiatry needs causal inference

Data-informed psychological therapy, measurement-based care, and precision mental health.

Moving towards precision psychiatry: the hard nut of depression

Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges

Challenges and prospects in bridging precision medicine and artificial intelligence in genomic psychiatric treatment

Personalized Cognitive Health in Psychiatry: Current State and the Promise of Computational Methods

Digital Phenotyping of Behavior and Clinical Decision Making in Psychogeriatrics: Towards Precision Care

Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics

Modern views of machine learning for precision psychiatry

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective